An MIT class project became an FDA-cleared wristband that eases essential tremor
A vibrating wristband first built as a foamcore prototype in MIT's product-design class is now FDA-cleared for adults with essential tremor. In two trials, more than 70% of patients improved. Insurance coverage is the next hurdle.

A wristband that calms shaking hands with vibration, first built by students in an MIT product-design class in 2017, has been cleared by the U.S. Food and Drug Administration for adults with essential tremor, MIT News reported on 2 October. The device, called Encora X1, is made by Encora Therapeutics, the company the students founded; three of them still work there. The FDA granted 510(k) clearance in February.
Essential tremor causes shaking, most often in the hands. MIT News describes it as a condition similar to Parkinson's disease.
A foamcore prototype stopped a man's tremor on stage
The idea came from Daniel Carballo, then a senior in MIT's class 2.009 (Product Engineering Processes). His team of about 17 students picked it by a 16-1 vote, with Carballo himself voting against because he thought it was too far-fetched for one semester.
The week before final presentations, they met Michael, a home renovator whose early-onset Parkinson's had made it hard to hold a screwdriver or fill out paperwork. Their prototype was, in Carballo's words, "a foamcore box with a Raspberry Pi chip and some wires coming out." At the presentation in MIT's Kresge Auditorium, Michael tried to draw a spiral, a common test for Parkinson's. Then he switched on the device, and within seconds he drew it far more precisely.
“When this device is turned on, I feel like I used to feel when I didn't have Parkinson's disease.” — Michael, at the 2017 class presentation
Vibration at the wrist reaches the brain regions targeted by surgery
The device vibrates stretch receptors in the wrist, which send a patterned signal through the nerves to the brain regions involved in tremor. Those are the same regions surgeons target when they implant electrodes in the brain. According to the company, the X1 analyzes a patient's tremor in real time and adjusts its stimulation.
The students formed Encora in 2020 and ran a first trial with 20 Parkinson's patients in 2022, with Mass General Brigham. They then switched to essential tremor, which affects more people. "There are a lot of drugs being developed for Parkinson's disease, but essential tremor hasn't experienced that same innovation," Carballo said. Parkinson's research has produced options such as a once-daily pill that cut symptom "off" time in a phase 3 trial.
In a randomized trial with 47 essential tremor patients in 2024, and a 59-person home-use study in 2025, more than 70% of patients had meaningful improvement, MIT News reported. Side effects listed by the company include numbness, skin rash, tingling and temporary worsening of tremor. The device is prescription-only.
Medicare enrollment rules slowed the rollout
Essential tremor is especially common in older people. In one major study, 75% of patients were 65 or older, the medical device industry group AdvaMed wrote in June. AdvaMed listed the existing options as medication that can need repeated dose changes and deep brain stimulation surgery that can last up to 12 hours.
AdvaMed, which counts Encora as a member, wrote that a six-month moratorium on new Medicare equipment-supplier enrollments, in effect from 27 February, blocked the company from completing its enrollment as a Medicare supplier. According to MIT News, Encora is now building a national sales force and seeking insurance coverage. Carballo said the company still hopes to treat Parkinson's tremor later.
Sources
- MIT News · news.mit.edu
- advamed.org
How we choose and verify sources: editorial policy.











